Table 1 Baseline characteristics of the eyes in different groups.
Total | Group A | Group B | Group C | p value | |
|---|---|---|---|---|---|
Number (eyes) | 164 | 75 | 78 | 11 | |
Age (year, Mean ± SD) | 59.32 ± 11.09 | 56.9 ± 10.9 | 62.2 ± 9.88 | 55.1 ± 15.7 | 0.002 |
Gender (male, %) | 51.8% | 52% | 50% | 63.6% | 0.6978 |
Laterality (OD, %) | 50.6% | 48.0% | 52.6% | 54.5% | 0.8221 |
DM treatment (insulin, %) | 36.1% | 27.7% | 42.3% | 45.5% | 0.1673 |
Hypertension (yes, %) | 80% | 67.1% | 89.5% | 100.0% | 0.0007 |
Baseline DR stage (%) | 0.4623 | ||||
Mild to Mod NPDR | 16.9% | 15.3% | 16.9% | 27.3% | |
Severe NPDR to PDR | 83.1% | 84.7% | 83.1% | 72.8% | |
Previous PRP (yes, %) | 61.0% | 64.0% | 59.0% | 54.5% | 0.7369 |
PRP number in 1st year (Mean ± SD) | 0.5 ± 0.9 | 0.5 ± 0.8 | 0.6 ± 1.1 | 0.5 ± 0.5 | 0.560749 |
Treatment Naïve (yes, %) | 89% | 93.3% | 84.6% | 90.9% | 0.2212 |
HbA1C (%, Mean ± SD) | 8.00 ± 1.65 | 8.46 ± 1.81 | 7.73 ± 1.36 | 6.95 ± 1.63 | 0.0021 |
Serum Hemoglobin (g/dl) (Mean ± SD) | 11.41 ± 1.85 | 12.29 ± 1.74 | 10.87 ± 1.67 | 10.51 ± 1.82 | 0.000083 |
Serum BUN (mg/dl, Mean ± SD) | 28.39 ± 16.91 | 16.7 ± 5.6 | 29.8 ± 12.9 | 60.0 ± 18.2 | < 0.001 |
Serum Albumin (g/dl, Mean ± SD) | 3.67 ± 0.46 | 3.78 ± 0.28 | 3.68 ± 0.49 | 3.53 ± 0.55 | 0.771410 |
Urine Albumin/Creatinine Ratio (Mean ± SD) | 3.42 ± 5.01 | 1.51 ± 2.47 | 3.70 ± 4.85 | 15.87 ± 5.00 | 0.000031 |
VA LogMAR (Mean ± SD) | 0.53 ± 0.34 | 0.50 ± 0.33 | 0.56 ± 0.33 | 0.55 ± 0.43 | 0.431852 |
CMT (μm, Mean ± SD) | 391.1 ± 118.0 | 381.1 ± 104.9 | 406.8 ± 130.7 | 332.6 ± 75.5 | 0.094272 |
Presence of SRF (%) | 28.0% | 22.9% | 32.9% | 30.0% | 0.4005 |
Presence of IRC (%) | 97.4% | 95.7% | 94.8% | 100.0% | 0.7522 |
Follow-up (month, mean ± SD) | 21.4 ± 4.4 | 21.4 ± 4.5 | 21.4 ± 4.4 | 21.1 ± 4.4 | 0.894849 |
